• At the EAACI 2026 congress in Istanbul, Pharvaris reported Phase 3 RAPIDe-3 data showing rapid, sustained efficacy and favorable safety for its oral deucrictibant capsule in treating hereditary angioedema attacks, alongside supportive long-term prophylaxis and cardiovascular safety findings.
• A distinctive feature of the update was the introduction of the End of Progression™ endpoint, highlighting how quickly deucrictibant can halt worsening symptoms and potentially improve patients’ day-to-day experience versus injectable treatments.
• We’ll now examine how this Phase 3 efficacy and safety profile for oral deucrictibant could shape Pharvaris’ broader investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

What Is Pharvaris' Investment Narrative?

To own Pharvaris today, you have to believe that deucrictibant can become a meaningful, dual‑use oral therapy for hereditary angioedema, across both on‑demand and prophylactic settings, before the company’s cash burn and dilution risks bite too hard. The EAACI data meaningfully sharpen that story: RAPIDe‑3 and the End of Progression endpoint reinforce the on‑demand case just as marketing filings are being prepared, while long‑term CHAPTER‑1 findings and cardiovascular safety work support the extended‑release prophylaxis program ahead of CHAPTER‑3 topline results in Q3 2026. With no revenue, ongoing losses and a price that has already more than doubled over twelve months, the near‑term catalysts now pivot even more clearly around regulatory feedback and the next Phase 3 readout, while the key risks remain trial, approval and financing outcomes.

However, one risk in particular could change the story faster than many investors expect. Pharvaris' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

The single fair value from the Simply Wall St Community clusters at US$46.05, suggesting some retail investors already factor in a strong deucrictibant profile. Set that against the heightened dependence on upcoming regulatory decisions and Phase 3 prophylaxis data, and you can see how opinions on Pharvaris’ longer term potential may still diverge widely. Readers should weigh these contrasting views before deciding how this aligns with their own expectations for the business.

Explore another fair value estimate on Pharvaris - why the stock might be worth as much as 38% more than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pharvaris research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.